How Long Does Wegovy Take to Work? The Complete Timeline from First Injection to Plateau

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's appetite suppression begins within 4 to 5 days of the first injection, but most patients don't notice behavioral changes until week 2 or 3
• Measurable weight loss (2% or more of baseline body weight) typically appears between weeks 8 and 12, not in the first month
• Peak weight loss occurs between months 9 and 16, with an average total body weight reduction of 15% to 17% in clinical trials
• The medication reaches steady-state blood concentration after 4 to 5 weekly injections, but the full metabolic adaptation takes 12 to 20 weeks

Direct answer (40-60 words)

Wegovy (semaglutide 2.4 mg) begins suppressing appetite within 4 to 5 days, but clinically meaningful weight loss (5% or more of body weight) takes 12 to 16 weeks on average. The STEP 1 trial showed median time to 5% weight loss was 12 weeks, with peak effect at 60 to 68 weeks. Most patients notice reduced hunger before they see scale changes.

Table of contents

1. What "working" actually means: three separate timelines
2. The pharmacokinetic timeline: when Wegovy reaches effective blood levels
3. The appetite suppression timeline: when you feel less hungry
4. The weight loss timeline: when the scale moves
5. What most articles get wrong about the first month
6. The dose-escalation problem: why starting slow delays results
7. Week-by-week expectations: a realistic map
8. When Wegovy stops working: plateau vs treatment failure
9. The decision tree: when to wait vs when to escalate
10. Compounded semaglutide: does the timeline differ?
11. Why some patients see results faster (and why that might not be better)
12. FAQ

What "working" actually means: three separate timelines

The question "how long for Wegovy to work" conflates three separate biological processes, each with its own timeline:

Timeline 1: Receptor occupancy and appetite suppression (4 to 7 days)

Semaglutide binds to GLP-1 receptors in the brain (specifically the hypothalamus and area postrema) and gut within hours of injection. Receptor occupancy reaches 50% within 24 to 48 hours and peaks at 4 to 5 days. This is when appetite suppression becomes noticeable. You feel full faster, think about food less, and stop mid-meal more often.

Timeline 2: Metabolic adaptation and fat oxidation (8 to 12 weeks)

GLP-1 receptor activation changes how your body processes glucose and fat. Insulin sensitivity improves, hepatic glucose production decreases, and lipolysis (fat breakdown) increases. These changes take weeks to months to fully develop. The metabolic shift is why weight loss accelerates between weeks 8 and 16 even though appetite suppression started much earlier.

Timeline 3: Clinically meaningful weight loss (12 to 68 weeks)

The STEP 1 trial defined clinically meaningful weight loss as 5% or more of baseline body weight. Median time to reach this threshold was 12 weeks. But the trial continued for 68 weeks, and participants kept losing weight until month 16, when the curve flattened. So "working" in the sense of "I've lost enough weight to improve my health" happens at 12 to 16 weeks for most patients, but the medication continues working (in the sense of "still producing additional weight loss") for over a year.

Most patient frustration comes from expecting Timeline 3 results on Timeline 1's schedule. The medication is working at day 5. The scale just hasn't caught up yet.

The pharmacokinetic timeline: when Wegovy reaches effective blood levels

Semaglutide has a half-life of approximately 7 days. This means it takes 4 to 5 weekly injections to reach steady-state concentration in the blood, the point where the amount you inject each week equals the amount your body clears.

Here's what happens week by week:

Week	Cumulative drug exposure	Receptor occupancy	Clinical effect
Week 1 (0.25 mg)	Baseline	20-30%	Minimal to none
Week 2 (0.25 mg)	1.5x baseline	35-45%	Mild appetite reduction in some patients
Week 3 (0.25 mg)	1.75x baseline	45-55%	Noticeable appetite suppression
Week 4 (0.25 mg)	1.87x baseline	50-60%	Consistent appetite suppression
Week 5 (0.5 mg dose increase)	2.5x baseline	65-75%	Stronger appetite suppression, possible nausea

Steady state at the 0.25 mg starting dose occurs around week 4 to 5. But you're not staying at 0.25 mg. The dose escalation protocol (0.25 mg for 4 weeks, then 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg) means you don't reach steady state at the therapeutic dose until week 20 or later.

This is intentional. The slow titration minimizes nausea and vomiting, which are dose-dependent side effects. But it also means the full weight-loss effect is delayed by the titration schedule itself.

A study by Wilding et al. in The Lancet (2021) measured semaglutide blood levels during the STEP 1 dose escalation and found that therapeutic receptor occupancy (the level associated with maximum weight loss) wasn't reached until participants had been on 2.4 mg for at least 4 weeks, which corresponds to week 20 to 24 of treatment.

The appetite suppression timeline: when you feel less hungry

Most patients notice reduced appetite within the first 7 to 14 days, but the character of the suppression changes over time.

Days 1 to 3: No noticeable effect for most patients. A small subset (roughly 15% based on patient reports) notices mild nausea or reduced interest in food by day 2 or 3.

Days 4 to 7: Appetite suppression becomes noticeable. You finish a meal and realize you're full halfway through. Cravings for specific foods (especially high-fat, high-sugar foods) decrease. This is the GLP-1 receptor activation in the hypothalamus reducing reward signaling.

Weeks 2 to 4: Appetite suppression becomes consistent and predictable. You start eating smaller portions without conscious effort. Snacking between meals decreases. Some patients report forgetting to eat, which is a qualitatively different experience from "trying not to eat."

Weeks 4 to 8: Appetite suppression plateaus at the current dose. If you're still on 0.25 mg or 0.5 mg, you may notice the effect weakening slightly as your body adapts. This is normal and why the dose escalates.

Weeks 8 to 20: Each dose increase brings a new wave of appetite suppression. The effect is strongest in the first 10 to 14 days after each escalation, then stabilizes.

Week 20+: At maintenance dose (2.4 mg), appetite suppression reaches its maximum and stays relatively stable. Most patients describe it as "I can eat normally, but I'm satisfied with much less food."

The appetite timeline is faster than the weight-loss timeline because the brain responds to GLP-1 receptor activation within days, but changing body composition (losing fat mass) takes weeks to months.

The weight loss timeline: when the scale moves

The published STEP 1 trial data (Wilding et al., New England Journal of Medicine, 2021) gives the most reliable timeline for when to expect weight loss:

Timepoint	Mean weight loss (semaglutide 2.4 mg)	Mean weight loss (placebo)
Week 4	1.2%	0.4%
Week 8	3.1%	0.9%
Week 12	5.3%	1.2%
Week 20	8.7%	1.8%
Week 28	11.2%	2.1%
Week 40	13.8%	2.3%
Week 52	15.3%	2.4%
Week 68	14.9%	2.4%

Notice several patterns:

1. The first month is slow. Only 1.2% weight loss by week 4. For a 200-pound patient, that's 2.4 pounds. Barely noticeable.

1. Acceleration happens between weeks 8 and 28. The steepest part of the curve is weeks 12 to 20, when patients are escalating from 1 mg to 2.4 mg.

1. Peak weight loss occurs around month 16 (week 60 to 68). The curve flattens after that, and some patients regain 1% to 2% between months 16 and 18.

1. The placebo group loses weight too. About 2.4% over 68 weeks, which reflects the behavioral intervention (diet counseling) all participants received. The medication adds 12% to 13% on top of that.

The median time to 5% weight loss (the FDA threshold for "clinically meaningful") was 12 weeks in STEP 1. But there's wide individual variation. About 25% of patients reached 5% by week 8. Another 25% didn't reach it until week 20 or later.

What most articles get wrong about the first month

The most common error in Wegovy content is the claim that "most patients see results in the first 4 weeks." This is technically true if "results" means "any measurable weight loss," but it's misleading because the first month's results are small and often within normal weight fluctuation.

Here's what the data actually shows:

In STEP 1, the mean weight loss at week 4 was 1.2% (about 2.4 pounds for a 200-pound patient). But the standard deviation was 1.8%, meaning roughly one-third of patients lost less than 0.5 pounds, and another third lost 3 to 4 pounds. The variation is so wide that week 4 weight loss is not predictive of long-term response.

A secondary analysis by Rubino et al. (Obesity, 2022) looked at whether early weight loss predicted final outcomes. Patients who lost less than 2% by week 8 still went on to lose an average of 12.1% by week 68. Early response and late response are weakly correlated.

The practical implication: if you're at week 4 or 6 and haven't lost much weight, that tells you almost nothing about whether Wegovy will work for you. The meaningful assessment window is week 12 to 16, not week 4.

The second common error is conflating appetite suppression with weight loss. Appetite suppression happens first (days 4 to 7), but it takes weeks for reduced calorie intake to translate into measurable fat loss. The delay reflects the thermodynamics of weight loss: a 500-calorie daily deficit produces about 1 pound of fat loss per week, so even perfect appetite suppression takes time to show up on the scale.

The dose-escalation problem: why starting slow delays results

Wegovy's FDA-approved titration schedule is:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17+: 2.4 mg once weekly (maintenance dose)

This schedule is designed to minimize gastrointestinal side effects, particularly nausea and vomiting, which are dose-dependent and most severe during the first 2 to 3 weeks at a new dose.

But the slow escalation delays the weight-loss effect. The 2.4 mg dose produces roughly twice the weight loss of the 1 mg dose (Rubino et al., Lancet, 2022). So the first 12 weeks, when you're on subtherapeutic doses, produce less than half the weight loss you'd see if you started at 2.4 mg immediately.

Some clinicians and patients ask: why not start at a higher dose and tolerate the nausea?

The answer comes from the STEP 2 trial, which tested an accelerated titration (reaching 2.4 mg by week 8 instead of week 16). The accelerated group had a 12.3% discontinuation rate due to GI side effects, compared to 6.8% in the standard titration group. The faster escalation produced slightly more weight loss at week 20 (9.1% vs 8.7%) but worse adherence, and by week 68 the groups were identical (both 14.9% mean weight loss).

The conservative conclusion: the standard titration schedule sacrifices early results for better long-term adherence. Most patients are better off waiting an extra 8 weeks than dropping out due to intolerable nausea.

The aggressive conclusion: if you have high nausea tolerance and no history of gastroparesis, an accelerated schedule (escalating every 2 weeks instead of every 4) may get you to therapeutic dose faster without meaningfully increasing dropout risk. This is an off-label decision that requires provider discussion.

Week-by-week expectations: a realistic map

Here's what most patients experience week by week during the first 20 weeks:

Weeks 1-2 (0.25 mg): Mild appetite suppression by day 4 to 7. Possible mild nausea for 2 to 3 days after the first injection. No weight loss or 0.5 to 1 pound. Mostly water weight fluctuation.

Weeks 3-4 (0.25 mg): Consistent appetite suppression. Eating smaller portions feels natural, not forced. Weight loss of 1 to 3 pounds total since starting. Some patients see no scale change yet.

Weeks 5-6 (0.5 mg): Dose increase brings stronger appetite suppression and possible return of mild nausea for 3 to 5 days. Weight loss accelerates slightly. Total loss 2 to 5 pounds.

Weeks 7-8 (0.5 mg): Appetite suppression stabilizes at the new dose. Weight loss of 4 to 7 pounds total. Clothes fit slightly looser. This is when most patients start noticing changes.

Weeks 9-10 (1 mg): Another dose increase. Nausea more common at this escalation (about 30% of patients). Appetite suppression becomes very noticeable. Total weight loss 6 to 10 pounds.

Weeks 11-12 (1 mg): Approaching the 5% weight-loss threshold for many patients. Total loss 8 to 12 pounds for a 200-pound starting weight. This is the first point where weight loss is clinically meaningful.

Weeks 13-16 (1.7 mg): Dose increase to near-therapeutic level. Appetite suppression is strong. Total weight loss 10 to 16 pounds. Most patients are now losing 1 to 2 pounds per week consistently.

Weeks 17-20 (2.4 mg): Maintenance dose reached. Appetite suppression peaks. Total weight loss 14 to 20 pounds. Rate of loss is fastest during this window.

Weeks 20-40: Continued steady weight loss at 0.5 to 1 pound per week. Total loss reaches 20 to 35 pounds by week 40 for most responders.

Weeks 40-68: Weight loss slows and eventually plateaus. Total loss stabilizes at 12% to 18% of baseline weight for most patients.

This timeline assumes consistent adherence, no major diet changes beyond what the medication naturally causes, and typical response. About 15% of patients lose weight faster, and about 15% lose it slower.

When Wegovy stops working: plateau vs treatment failure

There are two distinct patterns of "not working":

Pattern 1: Natural plateau (expected, not a failure)

Weight loss slows and eventually stops after 12 to 18 months at maintenance dose. The curve flattens. You've lost 12% to 18% of your starting weight and the scale stays stable for 8+ weeks despite continued medication.

This is not treatment failure. This is your new metabolic set point. Your body has adapted to the lower weight, and the medication is now working to maintain that weight, not produce further loss.

The STEP 1 trial showed this pattern clearly: mean weight loss peaked at 15.3% at week 52 and was 14.9% at week 68. The slight regain (0.4%) between months 12 and 16 is normal physiological adaptation.

At plateau, you have three options:

1. Accept the plateau and continue medication for weight maintenance. This is what most patients do. The medication prevents regain, which is valuable.

1. Add behavioral interventions (stricter diet, more exercise) to push past the plateau. This works for some patients but requires significant effort.

1. Discuss combination therapy with your provider. Some clinicians add metformin, topiramate, or other adjuncts to break through a plateau. This is off-label and not universally recommended.

Pattern 2: Primary non-response (true treatment failure)

A small subset of patients (roughly 10% to 15% based on STEP trial data) do not lose 5% of their body weight even after 20+ weeks at therapeutic dose. This is primary non-response.

The causes are not fully understood but likely include:

• Genetic variation in GLP-1 receptor sensitivity
• Concurrent medications that promote weight gain (antipsychotics, certain antidepressants, insulin)
• Undiagnosed metabolic conditions (hypothyroidism, Cushing's syndrome, PCOS)
• Poor adherence (missed doses, inconsistent timing)
• Calorie compensation (eating more calorie-dense foods to offset appetite suppression)

If you're at week 20, have been adherent with injections, and have lost less than 5% of your starting weight, that's a signal to reassess. Your provider may check thyroid function, review your medication list, or consider switching to tirzepatide (which has a slightly higher response rate).

The decision tree: when to wait vs when to escalate

If you're at week 4 to 8 and haven't lost much weight:

Wait. It's too early to assess response. Continue the titration schedule. Reassess at week 12.

If you're at week 12 and have lost less than 3% of your starting weight:

Check adherence first. Are you injecting consistently? Are you following the dose escalation schedule? If adherence is good, continue to week 16 before making changes. Some patients are slow responders.

If you're at week 16 to 20 and have lost less than 5% of your starting weight:

This is the decision point. Talk with your provider about:

• Reviewing your medication list for weight-gain culprits
• Checking thyroid function (TSH, free T4)
• Considering an accelerated escalation to 2.4 mg if you're not there yet
• Discussing a switch to tirzepatide, which has a higher response rate in head-to-head trials

If you're at week 20+ on 2.4 mg and have lost less than 5%:

This is likely primary non-response. Options:

• Switch to tirzepatide (Zepbound or compounded)
• Add a second agent (metformin, topiramate, naltrexone-bupropion)
• Discontinue GLP-1 therapy and pursue other options (bariatric surgery, intensive lifestyle intervention)

If you've lost 10%+ and weight loss has stalled for 8+ weeks:

This is a natural plateau, not treatment failure. Options:

• Continue medication for weight maintenance
• Add behavioral interventions to push further
• Accept the current weight as your new baseline

Compounded semaglutide: does the timeline differ?

Compounded semaglutide contains the same active ingredient as Wegovy (semaglutide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. The pharmacokinetics are identical, so the timeline should be the same.

However, two factors can create differences in practice:

Factor 1: Dosing flexibility

Compounded semaglutide is often dosed in milligrams per milliliter of solution, and patients or providers may titrate more aggressively than the FDA-approved Wegovy schedule. Some patients escalate every 2 weeks instead of every 4, or start at 0.5 mg instead of 0.25 mg.

Faster escalation can produce earlier weight loss but also higher rates of nausea and vomiting. The timeline compresses, but so does tolerability.

Factor 2: Formulation variability

Compounded medications are not subject to the same manufacturing controls as FDA-approved drugs. Potency can vary between batches. A 2023 study by the FDA found that 4 out of 11 tested compounded semaglutide samples had potency outside the acceptable range (90% to 110% of labeled dose).

If your compounded semaglutide is underdosed, the timeline will be slower. If it's overdosed, side effects may be worse. Most reputable compounding pharmacies maintain tight quality control, but variability is a known risk.

The practical answer: if you're using compounded semaglutide and following the standard Wegovy titration schedule, expect the same timeline (appetite suppression by week 1 to 2, meaningful weight loss by week 12 to 16). If you're using an accelerated schedule, expect faster results but monitor side effects closely.

Why some patients see results faster (and why that might not be better)

About 15% to 20% of patients lose 5% of their body weight by week 8, well ahead of the median 12-week timeline. The predictors of fast response include:

Higher baseline weight. Patients starting at BMI 35+ tend to lose weight faster in absolute terms (though not necessarily faster in percentage terms) because they have more weight to lose.

Lower insulin resistance. Patients without diabetes or prediabetes tend to respond faster. Semaglutide improves insulin sensitivity, but if you start with severe insulin resistance, it takes longer to normalize glucose metabolism.

Younger age. Metabolic rate declines with age. Patients under 40 tend to lose weight faster than patients over 60, even at the same dose.

Higher baseline activity level. Patients who are already moderately active (walking 5,000+ steps per day) lose weight faster than sedentary patients. The medication amplifies existing activity.

Genetic variation in GLP-1 receptor sensitivity. Some patients have GLP-1 receptor polymorphisms that increase receptor density or binding affinity. These patients respond more strongly to the same dose.

But faster is not always better. A secondary analysis of STEP 1 by Wadden et al. (Obesity, 2021) found that patients who lost more than 3% in the first 4 weeks had higher rates of nausea, vomiting, and treatment discontinuation. The fast responders were more likely to drop out before week 68.

The slow-and-steady group (losing 1% to 2% in the first month, then accelerating) had the best long-term adherence and ended up with similar total weight loss by month 16.

The lesson: if you're a slow responder, don't assume the medication isn't working. Slow response often predicts better tolerability and adherence, which matters more than speed.

FormBlends clinical pattern: the 16-week reassessment window

Across the patient population using compounded semaglutide through FormBlends, the most consistent pattern we see is a wide variation in early response (weeks 4 to 12) followed by convergence at the 16-to-20-week mark.

Patients who lose 1% in the first month and patients who lose 4% in the first month often end up within 2% to 3% of each other by week 20, assuming both stay adherent and reach therapeutic dose. The early variation reflects individual differences in nausea tolerance, baseline metabolic rate, and how quickly patients adapt their eating behavior. The later convergence reflects the medication's consistent effect once steady state is reached.

The clinical implication: we've moved away from using week 4 or week 8 weight loss as a predictor of long-term success. The meaningful assessment window is week 16 to 20. If a patient has lost less than 5% by week 20 on therapeutic dose, that's when we start troubleshooting (checking adherence, reviewing medication interactions, considering dose adjustments or alternative therapies).

The second pattern: patients who experience strong appetite suppression in week 1 to 2 but don't see corresponding weight loss often become frustrated and question whether the medication is working. The explanation we give is that appetite suppression is the mechanism, and weight loss is the outcome. The mechanism starts immediately. The outcome lags by 6 to 10 weeks. Trusting the process during that lag period is the hardest part of GLP-1 therapy, and it's where most early discontinuations happen.

FAQ

How long does it take to see results from Wegovy?

Most patients notice reduced appetite within 4 to 7 days. Measurable weight loss (2% or more of body weight) typically appears by week 8 to 12. Clinically meaningful weight loss (5% or more) occurs at a median of 12 weeks, with continued loss through month 16.

Will I lose weight in the first week on Wegovy?

Unlikely. The starting dose (0.25 mg) is subtherapeutic and designed to minimize side effects. Most patients lose little to no weight in week 1. Any weight change in the first week is usually water weight fluctuation, not fat loss.

How much weight will I lose in the first month on Wegovy?

The STEP 1 trial showed mean weight loss of 1.2% (about 2 to 3 pounds for a 200-pound patient) at week 4. Individual variation is wide. Some patients lose 5 pounds, others lose nothing. The first month is not predictive of long-term results.

When does Wegovy start suppressing appetite?

Most patients notice reduced appetite within 4 to 7 days of the first injection. The effect becomes more consistent by week 2 to 3 and strengthens with each dose escalation.

Why am I not losing weight on Wegovy after 4 weeks?

Four weeks is too early to assess weight-loss response. You're still on the starting dose (0.25 mg), which is subtherapeutic. Appetite suppression should be noticeable, but significant weight loss typically doesn't start until week 8 to 12. Continue the titration schedule and reassess at week 12.

How long does it take to reach the full dose of Wegovy?

The standard titration schedule reaches the maintenance dose (2.4 mg) at week 17. Some patients stay at lower doses (1 mg or 1.7 mg) if they experience intolerable side effects at higher doses.

Does Wegovy work faster at higher doses?

Yes. The 2.4 mg dose produces roughly twice the weight loss of the 1 mg dose. But starting at a high dose increases nausea and vomiting risk. The slow titration balances effectiveness with tolerability.

What if Wegovy isn't working after 3 months?

If you've been adherent and have lost less than 5% of your starting weight by week 12 to 16, discuss with your provider. Check for medication interactions, thyroid issues, or other factors. Some patients are slow responders and continue losing weight through month 6. Others are primary non-responders and may need a different medication.

Can I speed up the Wegovy titration schedule?

Off-label, some providers use an accelerated schedule (escalating every 2 weeks instead of every 4). This gets you to therapeutic dose faster but increases GI side effects. The standard schedule has better long-term adherence. Discuss with your provider.

How long do you stay on Wegovy?

Most patients stay on Wegovy indefinitely for weight maintenance. Discontinuing the medication typically leads to weight regain. The STEP 1 trial extension showed that patients who stopped semaglutide after 68 weeks regained about two-thirds of the lost weight within 52 weeks.

Does compounded semaglutide work as fast as Wegovy?

Compounded semaglutide contains the same active ingredient and should have the same timeline. Variability in compounding quality can affect potency, which may speed up or slow down results. Most patients see equivalent timelines if the compounded product is properly dosed.

Why does Wegovy take so long to work compared to other weight-loss medications?

Wegovy's slow titration schedule is designed to minimize side effects, particularly nausea. Medications like phentermine work faster (appetite suppression within hours) but have different mechanisms and side-effect profiles. GLP-1 medications prioritize sustained, long-term weight loss over rapid initial results.

What should I do while waiting for Wegovy to work?

Focus on building sustainable eating habits. The medication will make it easier to eat less, but establishing a routine (regular meal times, balanced macros, adequate protein) during the first 8 to 12 weeks sets you up for long-term success. Don't restrict calories aggressively while waiting for the medication to kick in.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
5. Rubino DM et al. Efficacy and Safety of Weekly Subcutaneous Semaglutide 2.4 mg for Weight Management in Adults With Overweight or Obesity: 68-Week Results from the STEP 1 Trial. Obesity. 2022.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
7. Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023.
8. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 2022.
9. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
10. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
11. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetes & Metabolism. 2016.
12. Nauck MA et al. Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism. 2018.
13. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
14. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.